Evidence map›Paper›PMID 39279775›Full record

ArticleNeuro-oncology practice2024

No drug holidays in BRAF

Danielle A Bazer, Anna Kolchinski, Nancy A O Bush, Jennifer L Clarke, Stephen J Bagley, Karisa C Schreck

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Danielle A BazerNational Cancer Institute, Neuro-Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9459-7773
Anna KolchinskiDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Nancy A O BushDepartments of Neurology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Jennifer L ClarkeDepartments of Neurology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Stephen J BagleyDepartment of Medicine, Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Karisa C SchreckDepartment of Neurology and Oncology, Johns Hopkins University, Baltimore, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Combined BRAF and MEK inhibition is effective for some BRAF Methods: This is a multi-institutional, retrospective review of 4 patients. Results: Three patients were diagnosed with BRAF Conclusions: Clinical and radiographic progression may occur rapidly upon holding BRAF-targeted therapy, warranting judicious dose reductions and minimization of drug holidays.

Indexed as

BRAF inhibitorBRAF V600Edrug holidaygliomaMEK inhibitor

Identifiers

PMID39279775
PMCPMC11398919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.